Lovenox HP en es it fr

Lovenox HP Brand names, Lovenox HP Analogs

Lovenox HP Brand Names Mixture

  • No information avaliable

Lovenox HP Chemical_Formula


Lovenox HP RX_link

Lovenox HP fda sheet

Lovenox_HP FDA

Lovenox HP msds (material safety sheet)

Lovenox HP Synthesis Reference

J. Mardiguian, Eur. pat. Appl. 40,144 (1981 to Pharmindustrie), C.A. 96, 218191s (1982)

Lovenox HP Molecular Weight

4500 daltons (average)

Lovenox HP Melting Point

No information avaliable

Lovenox HP H2O Solubility

> 200 mg/mL

Lovenox HP State


Lovenox HP LogP

No information avaliable

Lovenox HP Dosage Forms

Solution (for subcutaneous injection)

Lovenox HP Indication

For the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.

Lovenox HP Pharmacology

Enoxaparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Enoxaparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Enoxaparin is a well known and commonly used anticoagulant which has antithrombotic properties. Enoxaparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Enoxaparin acts at multiple sites in the normal coagulation system. Small amounts of enoxaparin in combination with antithrombin III (enoxaparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of enoxaparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Enoxaparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor.

Lovenox HP Absorption

Mean absolute bioavailability of enoxaparin, after 1.5 mg/kg given subcutaneously, based on anti-Factor Xa activity is approximately 100% in healthy volunteers.

Lovenox HP side effects and Toxicity

Mouse, median lethal dose greater than 5000 mg/kg. Another side effect is heparin induced thrombocytopenia (HIT syndrome). HIT is caused by an immunological reaction that makes platelets form clots within the blood vessels, thereby using up coagulation factors.

Lovenox HP Patient Information

No information avaliable

Lovenox HP Organisms Affected

Humans and other mammals